Cancer & Oncology Clinical Trials Update: Week 17, 2026

Published April 24, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC

This Phase III trial is testing a combination of two immunotherapy drugs, durvalumab and domvanalimab, in adults with locally advanced non-small cell lung cancer that cannot be removed by surgery. The treatment is given after standard chemoradiation, aiming to improve disease control and survival rates. If successful, this approach could provide patients with a new option that enhances long-term outcomes for a serious form of lung cancer.

A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC)

This study evaluates a new drug called Risvutatug rezetecan (Ris-Rez) for patients whose small cell lung cancer has returned after initial treatment. It compares Ris-Rez to the current standard therapy, topotecan, to see if it can better shrink tumors or extend survival with manageable side effects. The trial is active worldwide and may offer hope for improved therapies in this aggressive cancer type.

ECLECTIC: EstroTEP and Circulating Biomarkers for ER-positive HER2-negative Metastatic Breast Cancer Patients

This Phase III trial focuses on patients with metastatic breast cancer that is hormone receptor positive and HER2 negative. It aims to use advanced imaging and blood tests to personalize second-line treatments, combining endocrine therapy and chemotherapy. The goal is to improve how well treatments work by selecting the best options for each patient’s cancer characteristics.

A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

This trial compares two different combination treatments for adults with advanced non-small cell lung cancer who have a specific genetic mutation called KRAS p.G12C and no PD-L1 expression. It tests whether sotorasib combined with chemotherapy can improve survival compared to the current immunotherapy plus chemotherapy standard. If positive, this study could offer a new first-line treatment option tailored to genetic features.

Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)

This study evaluates a new oral drug combination for patients with hormone receptor-positive, HER2-negative metastatic breast cancer who have a specific ESR1 gene mutation. The goal is to delay disease progression compared to current hormone therapies, potentially improving the time patients live without their cancer worsening. The trial is recruiting worldwide and includes patients who have not yet seen their cancer progress on initial treatment.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.